Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, covers the reporting period ending March 25, 2025. The document serves as a conduit for a press release dated March 25, 2025, filed pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The provided filing text does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity within this document.
Material Changes
The filing text does not provide information regarding material changes compared to prior periods. The document consists solely of the cover page and exhibit index referencing an external press release.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, risk factors, contingencies, and unusual items are not detailed in the provided text. The filing references a press release (Exhibit 9.1) which likely contains these details, but the content of that release is not included in the input.
Investor Verification Checklist
- Verify the full content of the Press Release dated March 25, 2025 (Exhibit 9.1) referenced in this filing.
- Confirm whether the press release contains updated clinical trial data, regulatory milestones, or financial guidance.
- Review the company's most recent Form 20-F for the latest audited financial statements, as this 6-K does not include them.